Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes

Author(s):
Schouwenburg, M.G.; Jochems, A.; Leeneman, B.; Franken, M.G.; Eertwegh, A.J.M. van den; Haanen, J.B.A.G.; Zeijl, M.C.T. van; Aarts, M.J.; Akkooi, A.C.J. van; Berkmortel, F.W.P.J. van den; Blokx, W.A.M.; Groot, J.W.B. de; Hospers, G.A.P.; Kapiteijn, E.; Koornstra, R.H.; Kruit, W.H.; Louwman, M.W.J.; Piersma, D.; Rijn, R.S. van; Suijkerbuijk, K.P.M.; Tije, A.J. ten; Vreugdenhil, G.; Wouters, M.W.J.M.; Hoeven, J.J.M. van der
Published
2018
Publication type
Article / Letter to editor
clinical practicemetastatic melanomaprognostic factorsrisk scorevemurafenib
Date issued
2018-08-31
Language
English
Is part of
Melanoma Research (2018), Vol. 28, no. 4, p. 326-332
hdl
1887/96180
doi
10.1097/CMR.0000000000000453